Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients.

Trial Profile

Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients.

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Elbasvir/grazoprevir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms EGRADICATE
  • Most Recent Events

    • 02 Nov 2017 Planned End Date changed from 1 May 2018 to 1 Dec 2017.
    • 02 Nov 2017 Planned primary completion date changed from 1 May 2018 to 1 Jun 2017.
    • 02 Nov 2017 Planned initiation date changed from 1 Sep 2016 to 2 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top